Choice of a patient-reported outcome measure for patients with anal cancer for use in cancer clinical trials and routine clinical practice: a mixed methods approach.
Abstract
In the USA, more than 7200 new cases of anal cancer were diagnosed in 2014 with incidence rising. Concurrent chemoradiotherapy improves cancer-related outcomes but has led to an increase in acute and late adverse events. Patient-reported outcomes (PRO) are increasingly included in trials as a surrogate measure for reporting of late adverse events. This study aimed to select the most effective PRO to use in clinical research and practice for anal cancer since no questionnaire specific for anal cancer has been developed.Citation
Choice of a patient-reported outcome measure for patients with anal cancer for use in cancer clinical trials and routine clinical practice: a mixed methods approach. 2015, 385 Suppl 1:S38 LancetJournal
LancetDOI
10.1016/S0140-6736(15)60353-1PubMed ID
26312860Type
ArticleLanguage
enISSN
1474-547Xae974a485f413a2113503eed53cd6c53
10.1016/S0140-6736(15)60353-1
Scopus Count
Collections
Related articles
- Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Authors: Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, National Cancer Institute PRO-CTCAE Study Group.
- Issue date: 2015 Nov
- Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Authors: Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E, National Cancer Institute PRO-CTCAE Study Group.
- Issue date: 2016 Feb 19
- Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis.
- Authors: Ozgen Z, Ozden S, Atasoy BM, Ozyurt H, Gencosmanoglu R, Imeryuz N
- Issue date: 2015 Aug 12
- Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Authors: Bruner DW, Hanisch LJ, Reeve BB, Trotti AM, Schrag D, Sit L, Mendoza TR, Minasian L, O'Mara A, Denicoff AM, Rowland JH, Montello M, Geoghegan C, Abernethy AP, Clauser SB, Castro K, Mitchell SA, Burke L, Trentacosti AM, Basch EM
- Issue date: 2011 Mar
- The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events.
- Authors: Kawaguchi T, Azuma K, Sano M, Kim S, Kawahara Y, Sano Y, Shimodaira T, Ishibashi K, Miyaji T, Basch E, Yamaguchi T
- Issue date: 2017